Discontinued Product

RuBi-Dopa (Cat. No. 4932) has been withdrawn from sale for commercial reasons.
Cat.No. 4932 - RuBi-Dopa | C31H36Cl2N5O2PRu
Description: Caged dopamine; exhibits two-photon sensitivity
Chemical Name: (bis(2,2'-Bipyridine-N,N')trimethylphosphine)-(S)-(3,4-Dihydroxyphenyl)ethylamino ruthenium(2+) dichloride complex
Literature (5)

Biological Activity for RuBi-Dopa

RuBi-caged dopamine (Cat. No. 3548); exhibits two-photon sensitivity. Enables non-invasive, optical activation of dopamine receptors with the spatial resolution of a single dendritic spine. Does not display phototoxicity at a concentration of 300 μM.

Licensing Information

Sold under licence from Columbia University

Technical Data for RuBi-Dopa

M. Wt 713.6
Formula C31H36Cl2N5O2PRu
Storage Store at -20°C
PubChem ID 90488992
Smiles [Cl-].[Cl-].[Ru++].CP(C)C.NCCC1=CC=C(O)C(O)=C1.C1=CN=C(C=C1)C1=CC=CC=N1.C1=CC=C(N=C1)C1=CC=CC=N1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for RuBi-Dopa

Certificate of Analysis / Product Datasheet
Select another batch:

References for RuBi-Dopa

References are publications that support the biological activity of the product.

Araya et al (2013) Two-photon optical interrogation of individual dendritic spines with caged DA. ACS Chem. Neurosci. [Epub ahead of print] PMID: 23672485

View Related Products by Product Action

View all Non-selective Dopamine Agonists

Keywords: RuBi-Dopa, RuBi-Dopa supplier, caged, dopamine, two, photon, sensitive, sensitivity, microscopy, dopaminergic, neurons, high, resolution, dendritic, spines, Non-selective, Dopamine, Caged, Compounds, 4932, Tocris Bioscience

Citations for RuBi-Dopa

Citations are publications that use Tocris products.

Currently there are no citations for RuBi-Dopa.

Reviews for RuBi-Dopa

There are currently no reviews for this product. Be the first to review RuBi-Dopa and earn rewards!

Have you used RuBi-Dopa?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.


Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.